Get started
Author

Natasha E. Woodward

Observed names: N Woodward, N. Woodward, Natasha E Woodward, Natasha WOODWARD, Natasha Woodward, Woodward, Natasha
Observed institutions: Griffith University, F. Hoffmann-La Roche AG, Translational Research Institute, Mater Health Services, The Royal Melbourne Hospital, The University of Texas MD Anderson Cancer Center, Inserm, University of California, Los Angeles, The University of Queensland, Aix-Marseille Université, Royal Brisbane and Women's Hospital, Royal Perth Hospital, Rabin Medical Center, Fiona Stanley Hospital, Mater Misericordiae Hospital, Princess Alexandra Hospital, Samsung Medical Center, Seoul National University Hospital, Hospital General Universitario Gregorio Marañón, Hospital Clínico San Carlos, University of Ulsan, Mater Research, Chris O’Brien Lifehouse, Centre de Recherche en Cancérologie de Marseille, Institut Paoli-Calmettes, Mater Adult Hospital, UCSF Helen Diller Family Comprehensive Cancer Center, Indiana University School of Medicine, Technical University of Munich
ORCID: 0000-0003-0944-4807
Observed ORCID: 0000-0003-0944-4807
OpenAlex ID: A5027481104
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
2022 · C.E. Geyer, J.E. Garber, et al. · Annals of Oncology · 522
PDF
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
2020 · J.K. Litton, S.A. Hurvitz, et al. · Annals of Oncology · 439
PDF
Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies
2016 · Gwo Yaw Ho, Natasha Woodward, et al. · Critical Reviews in Oncology/Hematology · 341
Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab
2009 · James L. Hare, Joseph K. Brown, et al. · American Heart Journal · 228
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
2019 · T. Bachelot, E. Ciruelos, et al. · Annals of Oncology · 119
PDF
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication
2021 · D. Miles, E. Ciruelos, et al. · Annals of Oncology · 103
PDF
Exercise therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer
2020 · Kate E Roberts, Kirsty Rickett, et al. · Cochrane Database of Systematic Reviews · 74
Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis
2017 · Kate Roberts, Kirsty Rickett, et al. · Critical Reviews in Oncology/Hematology · 69
Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy
2019 · Hope S Rugo, Johannes Ettl, et al. · JNCI Cancer Spectrum · 31
PDF
Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer
2022 · Kate E Roberts, India T Adsett, et al. · Cochrane Database of Systematic Reviews · 27
A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors
2020 · Charlotte Lemech, Natasha Woodward, et al. · Investigational New Drugs · 26
Toxic optic neuropathy in the setting of docetaxel chemotherapy: a case report
2014 · Thomas P Moloney, Wen Xu, et al. · BMC Ophthalmology · 24
PDF
Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE)
2019 · Natasha Woodward, Richard H. De Boer, et al. · Clinical Breast Cancer · 22
Poor Muscle Status, Dietary Protein Intake, Exercise Levels, Quality of Life and Physical Function in Women with Metastatic Breast Cancer at Chemotherapy Commencement and during Follow-Up
2023 · Jessica Parkinson, Amelia Bandera, et al. · Current Oncology · 20
PDF
Neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant early-stage triple-negative breast cancer (TNBC): A single-arm phase 2 trial.
2022 · Sherene Loi, Prudence A. Francis, et al. · Journal of Clinical Oncology · 20
Maintaining Dose Intensity of Adjuvant Chemotherapy in Older Patients With Breast Cancer
2018 · Rahul Ladwa, Timothy Kalas, et al. · Clinical Breast Cancer · 18
Improved relapse-free survival on aromatase inhibitors in breast cancer is associated with interaction between oestrogen receptor-α and progesterone receptor-b
2018 · Cameron E. Snell, Madeline Gough, et al. · British Journal of Cancer · 14
PDF
Abstract CT071: Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): Final overall survival (OS) results from randomized Phase 3 EMBRACA trial
2020 · Jennifer K. Litton, Sara A. Hurvitz, et al. · Cancer Research · 10
Exercise therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer
2018 · Kate E Roberts, Kirsty Rickett, et al. · Cochrane Database of Systematic Reviews · 10
Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen
2017 · Cameron E Snell, Madeline Gough, et al. · Journal of Clinical Pathology · 10
Hormone receptor positive, HER2 negative metastatic breast cancer: A systematic review of the current treatment landscape
2016 · Jane BEITH, Katie BURSLEM, et al. · Asia-Pacific Journal of Clinical Oncology · 9
PDF
Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
2018 · Frances Boyle, Jane Beith, et al. · Asia-Pacific Journal of Clinical Oncology · 8
Single institution outcomes of treatment of severe aplastic anaemia
2001 · P. Mollee, N. Woodward, et al. · Internal Medicine Journal · 7
Abstract P4-21-31: Updated safety results from the first multicenter, open-label, phase IIIb study investigating the combination of pertuzumab with subcutaneous trastuzumab and a taxane in patients with HER2-positive metastatic breast cancer (SAPPHIRE)
2017 · N Woodward, RH De Boer, et al. · Cancer Research · 5
Incorporation of eribulin in the systemic treatment of metastatic breast cancer patients in Australia
2021 · Arlene Chan, Christopher Lomma, et al. · Asia-Pacific Journal of Clinical Oncology · 4
Works count: 51
Citation count: 2,173
H-index: 16
I10-index: 20
Year
Topic
Type